Know Cancer

forgot password

Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls

16 Years
Open (Enrolling)
Solid Carcinoma

Thank you

Trial Information

Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls

CD247 Known also as the zeta chain is important for relaying T-cell induced signal

Interestingly studies by Baniash and others have demonstrated that this chain is down
regulated in states of chronic inflammation and cancer in peripheral blood T cells and also
in NK cells However there has not been a prospective study of this marker in cancer and
control patients such a study will reveal not only the levels of CD247 in immune cells of
cancer patients compared to controls but may reveal the effect of anticancer therapies on
CD247 in cancer patients such a study may contribute significantly to our ability to monitor
systemic immune system characteristics in cancer patients and help in any further studies of
immunomodulation such as vaccination schemes in such patients

Inclusion Criteria:

- patients with cancer or blood donators agreeing to participate in the trial

Exclusion Criteria:

- other disease states which may cause chronic inflammation

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy

Outcome Description:

Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain

Outcome Time Frame:

4-2013 24 month

Safety Issue:


Principal Investigator

Hovav Nechushtan, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Oncology Dept Hadassah Hebrew University Medical Center


Israel: Ministry of Health

Study ID:




Start Date:

March 2011

Completion Date:

December 2013

Related Keywords:

  • Solid Carcinoma
  • cancer
  • immunomonitoring
  • CD247 -zeta chain
  • chronic inflamation
  • anticancertherapy
  • Carcinoma